Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2005, p. 1377-1380, Vol. 49, No. 4
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.4.1377-1380.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Azithromycin Exhibits Bactericidal Effects on Pseudomonas aeruginosa through Interaction with the Outer Membrane
Yoshifumi Imamura,1
Yasuhito Higashiyama,1*
Kazunori Tomono,1
Koichi Izumikawa,1
Katsunori Yanagihara,1
Hideaki Ohno,1
Yoshitsugu Miyazaki,1
Yoichi Hirakata,1
Yohei Mizuta,1
Jun-ichi Kadota,1
Barbara H. Iglewski,2 and
Shigeru Kohno1
Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan,1
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York2
Received 10 August 2004/
Returned for modification 28 November 2004/
Accepted 21 December 2004

ABSTRACT
The aim of the present study was to elucidate the effect of
the macrolide antibiotic azithromycin on
Pseudomonas aeruginosa.
We studied the susceptibility to azithromycin in
P. aeruginosa PAO1 using a killing assay. PAO1 cells at the exponential growth
phase were resistant to azithromycin. In contrast, PAO1 cells
at the stationary growth phase were sensitive to azithromycin.
The divalent cations Mg
2+ and Ca
2+ inhibited this activity,
suggesting that the action of azithromycin is mediated by interaction
with the outer membranes of the cells, since the divalent cations
exist between adjacent lipopolysaccharides (LPSs) and stabilize
the outer membrane. The divalent cation chelator EDTA behaved
in a manner resembling that of azithromycin; EDTA killed more
PAO1 in the stationary growth phase than in the exponential
growth phase. A 1-
N-phenylnaphthylamine assay showed that azithromycin
interacted with the outer membrane of
P. aeruginosa PAO1 and
increased its permeability while Mg
2+ and Ca
2+ antagonized this
action. Our results indicate that azithromycin directly interacts
with the outer membrane of
P. aeruginosa PAO1 by displacement
of divalent cations from their binding sites on LPS. This action
explains, at least in part, the effectiveness of sub-MICs of
macrolide antibiotics in pseudomonal chronic airway infection.

INTRODUCTION
Macrolide antibiotics have been used in the treatment of infections
caused by clinically important gram-positive cocci, such as
Streptococcus spp. and
Staphylococcus spp., and atypical pathogens,
such as
Mycoplasma spp.,
Chlamydia spp., and
Legionella spp.
The mechanism of antimicrobial activity of macrolides is generally
considered to be inhibition of microbial protein synthesis by
acting on the 50S subunit of the 70S ribosome (
17). In the 1990s,
the "new" macrolides, clarithromycin and azithromycin, were
released. The new macrolides have an expanded spectrum of activity,
including fastidious gram-negative bacilli, such as
Haemophilus influenzae and
Neisseria spp. However, macrolides have poor
activity against
Pseudomonas aeruginosa from the aspect of MIC
in vitro.
P. aeruginosa is one of the most important pathogens in patients with chronic airway infection, such as cystic fibrosis (CF) (12, 19) and diffuse panbronchiolitis (DPB) (6). When P. aeruginosa colonizes the airways of these patients, it is difficult to eradicate with antibiotics because of its ability to develop antibiotic resistance. In 1984, Kudoh et al. (8) reported the efficacy of macrolides in chronic airway infections, including DPB. Since then, most patients with DPB in Japan have been treated with macrolide antibiotics, and this therapy has been found to markedly improve the mortality of patients with DPB (7). In addition, recent studies reported that azithromycin also shows clinical efficacy in CF patients (14, 16).
Because the DPB patients are usually treated with sub-MIC concentrations of macrolide antibiotics, it has been considered that macrolides may affect the host defense mechanism and/or the expression of virulence of P. aeruginosa but that it has no bactericidal activity against P. aeruginosa.
In the present study, we show that azithromycin has a bactericidal effect against P. aeruginosa in certain bacterial growth phases. Our results also show that the direct effect of azithromycin on the outer membrane of P. aeruginosa might contribute to its bactericidal activity against this organism.

MATERIALS AND METHODS
Bacterial strains and growth conditions.
P. aeruginosa strain PAO1 was used in all experiments. It was
grown in peptone trypticase soy broth. For the experiments described
below, fresh medium was inoculated with an overnight culture
to a final dilution of 1:30 and grown with vigorous shaking
at 37°C.
Antibiotics and chemicals.
Azithromycin was provided by Pfizer Inc. (New York, N.Y.). Clarithromycin was provided by Abbott Japan Co. (Tokyo, Japan). Erythromycin was purchased from Sigma (St. Louis, Mo.). Gentamicin, EDTA, 1-N-phenylnaphthylamine (NPN), and KCN were purchased from Wako (Osaka, Japan).
Killing assay.
The bactericidal effects of compounds on P. aeruginosa were examined in two bacterial growth phases: the exponential phase and the stationary phase. After growth to an optical density at 600 nm of 0.5 (exponential phase) or 2.0 (stationary phase), azithromycin or EDTA was added to each phase of cells to the appropriate concentration with or without divalent cations. After coincubation for 8 h with vigorous shaking at 37°C, numbers of viable bacterial cells were determined by serial 10-fold dilution of samples plated on peptone trypticase soy agar (PTSA) plates and incubated at 37°C for 24 h. Experiments were performed in triplicate, and the results are expressed as means ± standard deviations.
Permeabilization of outer membrane to NPN.
The NPN assay was performed as described previously (5, 10). The cells were cultured to an optical density at 600 nm of 0.4 to 0.6. The cells were centrifuged at 3,000 x g for 10 min and resuspended in 5 mM HEPES buffer (pH 7.2) with 1 mM KCN at an optical density at 600 nm of 0.5. The cells were placed in a cuvette, and NPN was added to a final concentration of 10 µM. Compounds tested for the ability to permeabilize cells to NPN were added at the appropriate concentrations, and the increase in the NPN fluorescence intensity was monitored with a spectrofluorophotometer (RF-5300PC; Simazu Co., Tokyo, Japan). The excitation and emission wavelengths were set at 350 and 420 nm, with slit widths of 5 and 3 nm, respectively.

RESULTS
Effects of azithromycin on P. aeruginosa in different growth phases.
To determine the bactericidal activities of azithromycin against
different growth phases of
P. aeruginosa, we performed killing
assays in the exponential phase and in stationary phase. The
minimum bactericidal concentrations (MBCs, defined as the lowest
concentration of antibiotics that caused >99.9% reduction
of the bacterial count) of azithromycin against exponential-
and stationary-phase PAO1 were 128 and 1 µg/ml, respectively
(Fig.
1).
Effects of divalent cations on P. aeruginosa susceptibility to azithromycin.
We evaluated the effects of magnesium (Mg
2+) and calcium (Ca
2+)
ions on susceptibility to azithromycin in PAO1. Addition of
20 mg of Mg
2+/liter or 20 mg of Ca
2+/liter antagonized the bactericidal
activity of azithromycin against PAO1 (Fig.
2).
Effect of EDTA on P. aeruginosa in stationary phase.
We examined the effect of EDTA on PAO1 in each growth phase.
The MBCs of EDTA against exponential- and stationary-phase PAO1
were >4.0 and 0.2 mM, respectively (Fig.
3).
Effect of azithromycin on permeability of P. aeruginosa outer membrane.
To determine whether azithromycin affected the outer membrane
of
P. aeruginosa, we performed the NPN assay. No fluorescence
accumulation was evident when azithromycin was added to the
buffer containing NPN without cells (data not shown). The addition
of azithromycin to
P. aeruginosa cells in the presence of NPN
caused a time-dependent increase in fluorescence (Fig.
4A).
The addition of 8 µg of azithromycin/ml to
P. aeruginosa cells also caused an increase in fluorescence, but the activity
was weaker than that of 128 µg of azithromycin/ml. This
phenomenon was also observed when other macrolides, erythromycin
and clarithromycin, were added separately. However, the activities
of these agents were weaker than that of the same dose of azithromycin
(Fig.
4A). EDTA (Fig.
4B) and gentamicin (Fig.
4C) also caused
increases in fluorescence intensity. Ceftazidime, which showed
bactericidal activity against exponential-phase PAO1 but not
stationary-phase PAO1 in the killing assay (data not shown),
had no effect on the fluorescence intensity (Fig.
4D).
Inhibition of azithromycin enhancement of NPN fluorescence by divalent cations.
To confirm disrupted action on the outer membrane via replacement
of divalent cations with azithromycin, we investigated whether
the divalent cations inhibited the increase in NPN fluorescence.
We found that addition of the divalent cations Mg
2+ (1 mM) and
Ca
2+ (1 mM) inhibited the increase in NPN fluorescence induced
by azithromycin.

DISCUSSION
P. aeruginosa is a major pathogen causing chronic airway infection,
including DPB and CF. Because
P. aeruginosa lives in microcolonies
or biofilms in the airways of these patients (
15), most of the
organisms may be in stationary phase. The sensitivities of bacteria
to antibiotics are usually tested by the MIC method, which is
a measure of the drug concentration that inhibits bacterial
growth during the exponential phase. As shown in Fig.
1, when
P. aeruginosa PAO1 cells in the exponential phase were coincubated
with azithromycin, the MBC of azithromycin against PAO1 was
128 µg/ml, indicating that azithromycin had no bactericidal
activity against exponentially growing
P. aeruginosa. However,
when the bacteria had grown to stationary phase, the MBC decreased
from 128 to 1 µg/ml, suggesting that
P. aeruginosa became
sensitive to azithromycin (Fig.
1). These data seem to provide
the reason for the effectiveness of sub-MICs of macrolide antibiotics
in DPB patients. The reason why
P. aeruginosa in the stationary
phase was more sensitive to azithromycin than in the exponential
phase was not found in this study. Recently, it has been reported
that there are many differences between the gene expression
of
P. aeruginosa in the stationary phase and that in the exponential
phase (
18). Further studies are needed to determine whether
such differences in gene expression contribute to this phenomenon.
Polycationic antibiotics, such as aminoglycosides, are reported to disrupt the outer membrane of P. aeruginosa by acting to competitively displace divalent cations that cross-bridge adjacent lipopolysaccharide (LPS) molecules (3, 4). Antagonism of aminoglycosides by divalent cations is well documented for P. aeruginosa (1, 11, 20). Azithromycin is also a dicationic macrolide antibiotic. Farmer et al. (2) showed that azithromycin was capable of permeabilizing the outer membrane of Escherichia coli and that this action was antagonized by Mg2+. We also suspected that the bactericidal effect of azithromycin against P. aeruginosa was due to an aminoglycoside antibiotic-like action. Accordingly, we evaluated the effects of Mg2+ and Ca2+ on susceptibility to azithromycin in PAO1. We found that susceptibility to azithromycin in PAO1 was decreased by Mg2+ or Ca2+ (Fig. 2). These findings suggest that the mechanism of the bactericidal effect involves the displacement of divalent cations that cross-bridge adjacent LPS molecules. In addition, EDTA, which disrupts divalent-cation cross-bridges by chelation (4, 9), caused a similar bactericidal effect against P. aeruginosa (Fig. 3). These data supported the notion that displacement of divalent cations in the outer membrane caused bacterial cell death.
The outer monolayer of the outer membranes of gram-negative bacteria such as P. aeruginosa is constituted of LPS, and the outer membranes exclude hydrophobic compounds, including hydrophobic antibiotics (13) and the fluorescent probe NPN (10). Polycationic antibiotics can interact with the outer membrane at divalent-cation-binding sites on LPS, resulting in permeabilization of the outer membrane to hydrophobic compounds, such as NPN (5, 10). Thus, these probe molecules were utilized to observe the effect of azithromycin on outer membrane permeability. To determine whether azithromycin interacts with the outer membrane, we performed the NPN assay, which is commonly utilized to evaluate the interaction of compounds with the outer membrane. We demonstrated the enhancement of NPN uptake by azithromycin in intact bacterial cells, suggesting that azithromycin permeabilized the outer membrane of P. aeruginosa (Fig. 4A). Furthermore, Mg2+ or Ca2+ inhibited azithromycin-enhanced uptake of NPN (Fig. 5). This could be explained by competition between azithromycin and the divalent cations for a divalent-cation-binding site on the outer membrane.
In conclusion, our data indicate that azithromycin has bactericidal
activity against
P. aeruginosa. Azithromycin directly disrupted
the outer membrane of
P. aeruginosa, probably by displacement
of divalent cations from their binding sites on LPS on the outer
membrane. This direct action of azithromycin may contribute
to its bactericidal activity against
P. aeruginosa.

ACKNOWLEDGMENTS
We thank F. G. Issa (Word-Medex, Sydney, Australia) for his
assistance with editing the manuscript.
This work was partially supported by a grant from CFF Therapeutics (IGLEWSOOGO).

FOOTNOTES
* Corresponding author. Mailing address: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan. Phone: 81-95-849-7273. Fax: 81-95-849-7285. E-mail:
higashi-ngs{at}umin.ac.jp.


REFERENCES
1 - D'Amato, R., F. C. Thornsberry, C. N. Baker, and L. A. Kirven. 1975. Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin, polymyxin B, and carbenicillin. Antimicrob. Agents Chemother. 7:596-600.[Abstract/Free Full Text]
2 - Farmer, S., Z. S. Li, and R. E. Hancock. 1992. Influence of outer membrane mutations on susceptibility of Escherichia coli to the dibasic macrolide azithromycin. J. Antimicrob. Chemother. 29:27-33.[Abstract/Free Full Text]
3 - Hancock, R. E. 1981. Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. I. Antagonists and mutants. J. Antimicrob. Chemother. 8:249-276.[Free Full Text]
4 - Hancock, R. E., V. J. Raffle, and T. I. Nicas. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 19:777-785.[Abstract/Free Full Text]
5 - Hancock, R. E., and P. G. Wong. 1984. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 26:48-52.[Abstract/Free Full Text]
6 - Homma, H., A. Yamanaka, S. Tanimoto, M. Tamura, Y. Chijimatsu, S. Kira, and T. Izumi. 1983. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 83:63-69.[Abstract/Free Full Text]
7 - Kudoh, S., A. Azuma, M. Yamamoto, T. Izumi, and M. Ando. 1998. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 157:1829-1832.
8 - Kudoh, S., T. Uetake, M. Hagiwara, L. H. Hus, H. Kimura, and Y. Sugiyama. 1987. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn. J. Thorac. Dis. 25:632-642. (In Japanese with English abstract.)
9 - Leive, L., V. K. Shovlin, and S. E. Mergenhagen. 1968. Physical, chemical, and immunological properties of lipopolysaccharide released from Escherichia coli by ethylenediaminetetraacetate. J. Biol. Chem. 243:6384-6391.[Abstract/Free Full Text]
10 - Loh, B., C. Grant, and R. E. Hancock. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551.[Abstract/Free Full Text]
11 - Medeiros, A. A., T. F. O'Brien, W. E. Wacker, and N. F. Yulug. 1971. Effect of salt concentration on the apparent in-vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin. J. Infect. Dis. 124(Suppl.):59-64.
12 - Neu, H. C. 1983. The role of Pseudomonas aeruginosa in infections. J. Antimicrob. Chemother. 11(Suppl. B):1-13.[Free Full Text]
13 - Nikaido, H., and M. Vaara. 1985. Molecular basis of bacterial outer membrane permeability. Microbiol. Rev. 49:1-32.[Free Full Text]
14 - Saiman, L., B. C. Marshall, N. Mayer-Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette, A. Y. Fieberg, F. J. Accurso, and P. W. Campbell III. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756.[Abstract/Free Full Text]
15 - Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, and E. P. Greenberg. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764.[CrossRef][Medline]
16 - Southern, K. W., P. M. Barker, and A. Solis. 27 May 2003, posting date. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev.:CD002203. [Online.]
17 - Taubman, S. B., N. R. Jones, F. E. Young, and J. W. Corcoran. 1966. Sensitivity and resistance to erythromycin in Bacillus subtilis 168: the ribosomal binding of erythromycin and chloramphenicol. Biochim. Biophys. Acta 123:438-440.[Medline]
18 - Wagner, V. E., D. Bushnell, L. Passador, A. I. Brooks, and B. H. Iglewski. 2003. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. Bacteriol. 185:2080-2095.[Abstract/Free Full Text]
19 - Wood, R. E., T. F. Boat, and C. F. Doershuk. 1976. Cystic fibrosis. Am. Rev. Respir. Dis. 113:833-878.[Medline]
20 - Zimelis, V. M., and G. G. Jackson. 1973. Activity of aminoglycoside antibiotics against Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J. Infect. Dis. 127:663-669.[Medline]
Antimicrobial Agents and Chemotherapy, April 2005, p. 1377-1380, Vol. 49, No. 4
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.4.1377-1380.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Mulet, X., Macia, M. D., Mena, A., Juan, C., Perez, J. L., Oliver, A.
(2009). Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants. Antimicrob. Agents Chemother.
53: 1552-1560
[Abstract]
[Full Text]
-
Kohler, T., Dumas, J.-L., Van Delden, C.
(2007). Ribosome Protection Prevents Azithromycin-Mediated Quorum-Sensing Modulation and Stationary-Phase Killing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
51: 4243-4248
[Abstract]
[Full Text]
-
Hoffmann, N., Lee, B., Hentzer, M., Rasmussen, T. B., Song, Z., Johansen, H. K., Givskov, M., Hoiby, N.
(2007). Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr / Mice. Antimicrob. Agents Chemother.
51: 3677-3687
[Abstract]
[Full Text]